{"id":5362,"date":"2021-12-16T22:24:46","date_gmt":"2021-12-16T19:24:46","guid":{"rendered":"https:\/\/www.klimik.org.tr\/koronavirus\/?p=5362"},"modified":"2022-01-03T16:36:55","modified_gmt":"2022-01-03T13:36:55","slug":"klimik-derneginden-omikrona-karsi-asi-onerileri","status":"publish","type":"post","link":"https:\/\/www.klimik.org.tr\/koronavirus\/klimik-derneginden-omikrona-karsi-asi-onerileri\/","title":{"rendered":"KL\u0130M\u0130K Derne\u011fi’nden Omikrona Kar\u015f\u0131 Ba\u011f\u0131\u015f\u0131klama \u00d6nerileri"},"content":{"rendered":"

(7. madde 3 Ocak 2022 tarihinde g\u00fcncellenmi\u015ftir.)<\/em><\/p>\n

Klimik Derne\u011fi olarak daha \u00f6nce yapm\u0131\u015f oldu\u011fumuz bilgilendirmelerde belirtti\u011fimiz \u00fczere Omikron varyant\u0131 \u00f6nceki varyantlara k\u0131yasla hem daha bula\u015f\u0131c\u0131 hem de antikorlardan daha az etkilenen bir varyantt\u0131r. Bu \u00f6zellikleri nedeniyle a\u015f\u0131lanan ve\/veya hastal\u0131\u011f\u0131 daha \u00f6nce ge\u00e7irmi\u015f ki\u015filerde COVID-19 geli\u015fmesine ve d\u00fcnya genelinde olgular\u0131n h\u0131zla artmas\u0131na neden olmaktad\u0131r. Omikron varyant\u0131n\u0131n yay\u0131l\u0131m\u0131n\u0131n \u00f6nlenmesi bireylerin hastal\u0131ktan korunabilmesi i\u00e7in ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n g\u00fc\u00e7l\u00fc olmas\u0131 gerekmektedir. Halen COVID-19\u2019a kar\u015f\u0131 uygulanmakta olan a\u015f\u0131lar\u0131n etkinli\u011fi azalmakla beraber devam etmektedir. Yap\u0131lan \u00e7al\u0131\u015fmalar hat\u0131rlatma dozlar\u0131n\u0131n uygulanmas\u0131n\u0131n korunmay\u0131 belirgin olarak art\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6stermektedir.<\/p>\n

Klimik Derne\u011fi olarak ba\u011f\u0131\u015f\u0131klama \u00f6nerilerimizi, Omikron varyant\u0131n\u0131n olu\u015fturdu\u011fu yak\u0131n tehdit nedeniyle, mevcut veriler (\u00f6ncelikle klinik \u00e7al\u0131\u015fma sonu\u00e7lar\u0131 ve ger\u00e7ek ya\u015fam verileri, bu verilerin olmad\u0131\u011f\u0131 durumlardaysa a\u015f\u0131 imm\u00fcnojenisitesi ve n\u00f6tralizasyon kapasiteleriyle ilgili yap\u0131lm\u0131\u015f laboratuvar \u00e7al\u0131\u015fmalar\u0131n\u0131n verileri) \u0131\u015f\u0131\u011f\u0131nda 18 ya\u015f\u0131ndan b\u00fcy\u00fck herkes i\u00e7in ge\u00e7erli olmak \u00fczere a\u015fa\u011f\u0131daki gibi g\u00fcncellemi\u015f bulunuyoruz:<\/p>\n

    \n
  1. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filerin bir ay arayla iki doz BioNTech olduktan en erken 3 ay sonra 3. doz BioNTech a\u015f\u0131lar\u0131n\u0131 olmalar\u0131 \u00f6nerilir.<\/li>\n
  2. Hi\u00e7 a\u015f\u0131lanmam\u0131\u015f ki\u015filere mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*<\/strong> Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131laman\u0131n ard\u0131ndan en erken 3 ay sonra hat\u0131rlatma dozu yap\u0131lmas\u0131 \u00f6nerilir.<\/li>\n
  3. \u00c7e\u015fitli nedenlerle primer a\u015f\u0131 \u015femas\u0131 (Sinovac i\u00e7in 0,1, 4. aylarda 3 doz, BioNTech i\u00e7in bir ay arayla iki doz) yar\u0131m kalan ki\u015filerin a\u015f\u0131lamalar\u0131na kald\u0131klar\u0131 yerden devam edilmesi, hat\u0131rlatma dozlar\u0131n\u0131n primer \u015feman\u0131n tamamlanmas\u0131ndan en erken 3 ay sonra yap\u0131lmas\u0131 \u00f6nerilir.<\/li>\n
  4. \u0130ki doz BioNTech a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin 2. dozdan en erken 3 ay sonra hat\u0131rlatma dozunu olmalar\u0131 \u00f6nerilir.<\/li>\n
  5. \u00dc\u00e7 doz Sinovac a\u015f\u0131s\u0131 olmu\u015f ki\u015filerin son dozdan en erken 3 ay sonra hat\u0131rlatma dozlar\u0131n\u0131 (tercihen BioNTech a\u015f\u0131s\u0131 ile) olmalar\u0131 \u00f6nerilir.<\/li>\n
  6. \u0130ki doz Sinovac ve bir doz BioNTech a\u015f\u0131s\u0131 olanlar\u0131n ikinci doz BioNTech a\u015f\u0131lar\u0131n\u0131 son a\u015f\u0131dan en erken 3 ay sonra olmalar\u0131 \u00f6nerilir.<\/li>\n
  7. \u0130ki doz Sinovac ard\u0131ndan iki doz BioNTech a\u015f\u0131s\u0131 (toplam 4 doz a\u015f\u0131) olanlar i\u00e7erisinde 65 ya\u015f\u0131n \u00fczerinde olanlar, ba\u011f\u0131\u015f\u0131kl\u0131k yetersizli\u011fi olanlar (hastal\u0131k veya ilaca ba\u011fl\u0131), altta yatan ciddi hastal\u0131\u011f\u0131 olanlar (b\u00f6brek yetmezli\u011fi, kalp yetmezli\u011fi vb.) ve y\u00fcksek miktarda virusla kar\u015f\u0131la\u015fma riski olan ki\u015filer (sa\u011fl\u0131k \u00e7al\u0131\u015fanlar\u0131) hat\u0131rlatma dozunu, son a\u015f\u0131dan 3 ay sonradan itibaren olabilirler. Bu gruplar d\u0131\u015f\u0131nda kalan ki\u015filerin hat\u0131rlatma dozunu 6 aydan \u00f6nce olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. Alt\u0131nc\u0131 ayda yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/li>\n
  8. Hastal\u0131k ge\u00e7irdikten sonra iki doz BioNTech olanlar\u0131n hat\u0131rlatma dozunu 6 aydan \u00f6nce olmalar\u0131na \u015fimdiki bilgilere g\u00f6re gerek yoktur. Alt\u0131nc\u0131 ayda yeni veriler \u0131\u015f\u0131\u011f\u0131nda de\u011ferlendirilmelidir.<\/li>\n
  9. Hastal\u0131k ge\u00e7irdikten sonra iki doz Sinovac olanlar\u0131n, hat\u0131rlatma dozunu ikinci Sinovac\u2019tan 3 ay sonra (tercihen BioNTech ile) olmalar\u0131 \u00f6nerilir.<\/li>\n
  10. \u0130ki doz Sinovac olmas\u0131na ra\u011fmen hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin hastal\u0131ktan 3 ay sonra bir doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131, hat\u0131rlatma dozlar\u0131n\u0131 bu a\u015f\u0131dan 3 ay sonra yapt\u0131rmalar\u0131 \u00f6nerilir. mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*<\/strong> Sinovac a\u015f\u0131s\u0131 ile hastal\u0131ktan 3 ay sonra ba\u015flamak \u00fczere \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/li>\n
  11. \u0130ki doz BioNTech olmas\u0131na ra\u011fmen hastal\u0131k ge\u00e7irmi\u015f olan ki\u015filerin hastal\u0131ktan en az 3 ay sonra bir doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131 \u00f6nerilir.<\/li>\n
  12. A\u015f\u0131 \u015femas\u0131 tamamlanmadan veya hi\u00e7 a\u015f\u0131lanmadan hastalanm\u0131\u015f ki\u015filerin, hastal\u0131ktan en erken 1 ay sonra ba\u015flayarak 1 ay arayla iki doz BioNTech a\u015f\u0131s\u0131 olmalar\u0131, mRNA a\u015f\u0131s\u0131 yap\u0131l(a)mad\u0131\u011f\u0131 durumda*<\/strong> Sinovac a\u015f\u0131s\u0131 ile \u00fc\u00e7 doz (0, 1 ve 4. aylarda) a\u015f\u0131lanmalar\u0131 \u00f6nerilir.<\/li>\n
  13. Ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan ki\u015filerin inaktif a\u015f\u0131 yerine mRNA a\u015f\u0131lar\u0131 ile a\u015f\u0131lanmalar\u0131 \u00f6nerilir. Bu ki\u015filer 1 ay arayla 3 dozdan (BioNTech) olu\u015fan primer a\u015f\u0131 \u015femas\u0131n\u0131 tamamlad\u0131ktan sonra ek dozlar\u0131n say\u0131s\u0131 ve zamanlamas\u0131n\u0131n belirlenmesi i\u00e7in \u0130nfeksiyon Hastal\u0131klar\u0131 ve Klinik Mikrobiyoloji uzmanlar\u0131na ba\u015fvurmalar\u0131 \u00f6nerilir.<\/li>\n<\/ol>\n

    *<\/strong> A\u015f\u0131ya eri\u015fmede g\u00fc\u00e7l\u00fck, a\u015f\u0131 i\u00e7eri\u011fine anafilaktik tipte alerjik yan\u0131t, ki\u015finin tercih etmemesi vb. durumlar.<\/em><\/p>\n

    KL\u0130M\u0130K Derne\u011fi Y\u00f6netim Kurulu<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

    (7. madde 3 Ocak 2022 tarihinde g\u00fcncellenmi\u015ftir.) Klimik Derne\u011fi olarak daha \u00f6nce yapm\u0131\u015f oldu\u011fumuz bilgilendirmelerde belirtti\u011fimiz \u00fczere Omikron varyant\u0131 \u00f6nceki varyantlara k\u0131yasla hem daha bula\u015f\u0131c\u0131 hem de antikorlardan daha az etkilenen bir varyantt\u0131r. Bu \u00f6zellikleri nedeniyle a\u015f\u0131lanan ve\/veya hastal\u0131\u011f\u0131 daha \u00f6nce ge\u00e7irmi\u015f ki\u015filerde COVID-19 geli\u015fmesine ve d\u00fcnya genelinde olgular\u0131n h\u0131zla artmas\u0131na neden olmaktad\u0131r. Omikron varyant\u0131n\u0131n yay\u0131l\u0131m\u0131n\u0131n \u00f6nlenmesi bireylerin hastal\u0131ktan korunabilmesi i\u00e7in ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131n\u0131n g\u00fc\u00e7l\u00fc olmas\u0131 gerekmektedir. Halen COVID-19\u2019a kar\u015f\u0131 uygulanmakta olan a\u015f\u0131lar\u0131n etkinli\u011fi azalmakla beraber devam etmektedir. Yap\u0131lan \u00e7al\u0131\u015fmalar hat\u0131rlatma dozlar\u0131n\u0131n uygulanmas\u0131n\u0131n korunmay\u0131 belirgin olarak art\u0131rd\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. Klimik Derne\u011fi olarak ba\u011f\u0131\u015f\u0131klama \u00f6nerilerimizi, Omikron varyant\u0131n\u0131n olu\u015fturdu\u011fu yak\u0131n tehdit nedeniyle, mevcut veriler […]<\/p>\n","protected":false},"author":4,"featured_media":5364,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5362"}],"collection":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/comments?post=5362"}],"version-history":[{"count":7,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5362\/revisions"}],"predecessor-version":[{"id":5451,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/posts\/5362\/revisions\/5451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media\/5364"}],"wp:attachment":[{"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/media?parent=5362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/categories?post=5362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.klimik.org.tr\/koronavirus\/wp-json\/wp\/v2\/tags?post=5362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}